Based on prevention of prison disease by transgenic anti-prison protein (Prep) antibody expression in mice, we propose to develop a vaccine to actively induceati-prion immunity in mice. For this purpose, immunological self-tolerance against Prep will be analysed. On that basis recombinant virus vaccines will be developed to explore immunological intervention strategies. The consortium consists of 4 research groups conversing different fields of expertise, i.e. immunology, prison biology, antibody engineering, and recombinant virus technology. The studies will involve advanced technologies to develop new gene targeted mouse models, to establish recombinant Rhabdovirus vaccines, and to optimise anti-PrPantibodies. The results of these studies will explore the feasibility of prionvaccination in mice and will open future perspectives for developing scrapievaccines for animals and humans.
Funding SchemeCSC - Cost-sharing contracts